A pharma retail acquisition case where Mallgreens considers acquiring smaller competitor BrightAid. Candidates must evaluate consolidation opportunities across states, make granular store closure decisions based on distance and profitability metrics, and understand regulatory implications of different purchase structures.
Key Insights:
- Consolidation opportunities depend on geographic overlap—focus on states where both companies have significant presence (CA, NY, TX)
- Retail presence (footprint) is a critical success factor that may justify retaining some loss-making stores strategically positioned for market coverage
- Store closure decisions require distance-based tiering: close immediate duplicates (<0.5mi), evaluate mid-range stores (0.5-2mi) with customer surveys, and invest in distant stores (>2mi) for transformation
- Purchase structure (stock vs. asset) has major implications for regulatory compliance—asset purchase allows selective store acquisition to stay within FTC thresholds, while stock purchase requires post-deal divestitures
- Synergy sources include cost savings (buying power, footprint consolidation, corporate overhead) and revenue opportunities (selling power, new locations for complementary services)